Purpose: To compare outcomes in patients with treatment-na€ ıve neovascular agerelated macular degeneration (nAMD) receiving ranibizumab treat and extend (TE) with those receiving ranibizumab pro re nata (PRN) in a clinical setting. Methods: During this 12-month retrospective, consecutive, comparative case series, patients received ranibizumab 0.5 mg according to a TE or PRN regimen. Monthly optical coherence tomography (OCT) evaluation was performed during the PRN regimen; retreatment criteria included recurrence of intra-/subretinal fluid, or haemorrhages. During the TE regimen, initial treatment with 4-week intervals was sequentially lengthened by 2 weeks until signs of choroidal neovascularization (CNV) activity recurred. Study end-points included mean change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), mean injection frequency and number of follow-up visits attended. Results: Baseline characteristics were similar between the TE (n = 70) and PRN (n = 70) groups. Mean change in BCVA from baseline to Month 12 was significantly greater in the TE group than the PRN group (+0.18 AE 0.17 versus +0.07 AE 0.20, p < 0.001). Mean change in CRT from baseline to Month 12 was greater in the TE group than the PRN group (À116 AE 132 versus À58 AE 157 lm, p = 0.019). The number of follow-up visits attended was significantly higher in the PRN group than the TE group (11.9 AE 1.1 versus 8.6 AE 1.9, p < 0.001), while patients in the TE group received more injections during the study than those in the PRN group (8.6 AE 1.9 versus 6.0 AE 1.9, p < 0.001). Conclusion: Ranibizumab administered using a TE regimen in treatment-na€ ıve patients with nAMD provided better visual outcomes with fewer clinic visits, compared with a PRN regimen.
Introduction
Neovascular age-related macular degeneration (nAMD) causes severe vision loss, frequently resulting in legal blindness (Wong et al. 2008; Mitchell et al. 2010) . Ranibizumab became available for the treatment of nAMD in 2006, and was rapidly regarded as the standard of care (Schmidt-Erfurth et al. 2014) . A recent update to the current European Summary of Product Characteristics for ranibizumab enables flexible monitoring and retreatment of patients (Novartis 2014). However, a number of different individualized dosing regimens are currently practiced in the clinic and the comparative benefits of each are unclear.
A variety of different ranibizumab dosing schedules have been investigated; the MARINA and ANCHOR studies investigated simple monthly injections and found them efficient and well-tolerated Rosenfeld et al. 2006) . Less frequent treatment schedules were then investigated in an effort to decrease the burden to patients/clinicians; however, this produced inferior visual acuity (VA) outcomes when compared with monthly dosing, possibly as a result of under-treatment (Abraham et al. 2010; Schmidt-Erfurth et al. 2011) . Subsequent trials investigated variations of an individualized pro re nata (PRN) regimen (Boyer et al. 2009; Lalwani et al. 2009; Holz et al. 2011; Martin et al. 2012; Busbee et al. 2013) . A PRN regimen includes a loading dose of usually three monthly intravitreal injections followed by monthly observations with treatment resumption instigated when new signs of choroidal neovascularization (CNV) activity are identified by optical coherence tomography (OCT) and/or haemorrhages are observed, or upon loss of VA. Whilst VA gains were generally lower than with monthly dosing, clinically meaningful improvements in VA were obtained with fewer injections (Boyer et al. 2009; Lalwani et al. 2009; Holz et al. 2011; Martin et al. 2012; Busbee et al. 2013 ). Nevertheless, a PRN regimen can place a high burden on patients/healthcare services due to the monthly monitoring visits. Moreover, while large prospective long-term studies such as HARBOR have demonstrated VA gains are sustained with PRN at 24 months (Ho et al. 2014) , some evidence exists that a reduction in VA can occur with this regimen after the initial 3-month loading phase . Consequently, alternative individualized regimens, such as 'treat and extend' (TE) have recently gained acceptance (Spaide 2007; Engelbert et al. 2009 Engelbert et al. , 2010 . Following 4-weekly injections until the establishment of stable disease, treatment and monitoring intervals are extended in a TE regimen, thereby reducing the need for monthly clinic visits. Results from mostly smaller TE studies have been promising, with improved VA compared with PRN protocols and comparable VA outcomes to those observed in the trials of monthly ranibizumab being observed (Gupta et al. 2010; Oubraham et al. 2011; Toalster et al. 2013; Abedi et al. 2014; Berg et al. 2015; Rayess et al. 2015) . However, published studies in larger populations with direct comparisons to other treatment strategies remain rare.
This retrospective, interventional, consecutive case series aimed to compare the clinical effectiveness and safety outcomes in patients with treatmentna€ ıve nAMD who received ranibizumab injections in either a PRN or TE regimen. Study end-points included best-corrected visual acuity (BCVA), central retinal thickness (CRT), frequency of injections and frequency of visits.
Patients and Methods
Patient selection, study design and treatment intervention
This was a retrospective study consisting of two consecutive, comparative case series. Patients meeting the inclusion criteria were Caucasians with active [OCT, Fluorescein angiography (FA)-proven] treatment-na€ ıve nAMD and with a baseline BCVA ≥0.05 (Snellen). All CNV subtypes were included. Patients were excluded if they experienced haemorrhages of >0.50% of total lesion size or an inability to perform FA at baseline. Each series consisted of 70 consecutive patients who met the above inclusion/exclusion criteria and completed a 1-year follow-up. During the first case series (2010) (2011) (2012) , patients received ranibizumab 0.5 mg PRN from treatment initiation. In the second case series (2012) (2013) (2014) , patients received ranibizumab 0.5 mg TE.
A summary of the treatment regimens and study design are presented in Fig. 1 . All treatment decisions were made by a defined retina specialist team under the supervision of two leading retina specialists.
All intravitreal injections (0.5 mg ranibizumab) were performed according to standard procedures, including topical anaesthesia and surface disinfection with 5% povidone-iodine.
All OCT analyses were performed using a SD-OCT system (Spectralis, Heidelberger Eng., Germany). At each visit, the following fovea-centred scans were performed: horizontal volume scan (19 sections; for quantitative and qualitative evaluation), macular star (six sections; for qualitative evaluation), and a horizontal follow-up 6 mm scan. CRT was defined as the central subfield thickness (ETDRS field) measured using the volume scan after exact centring of the scan and alignment of the automated lines (basal membrane and inner limiting membrane). Qualitative assessments (subor intraretinal fluid in any scan), as well as quantitative assessments (CRT), were retrospectively performed by one leading retina specialist.
All patients were treated at the Vista Klinik, Binningen, Switzerland and the study followed the tenets of the Declaration of Helsinki. Approval was received from the local ethics approval board [Ethikkommission Nordwestschweiz (EKNZ No. 2014-189) ].
Data analysis
Data are presented as mean (AE standard deviation) or percentage.
Differences between the groups were tested for statistical significance with unpaired t-tests, differences during follow-up within each group with paired t-tests. p Values (2-sided) were considered significant if p < 0.05. Intra-individual differences in VA (range between minimum and maximum VA achieved per patient) between Month 3 and 12 were calculated; in an analogous manner the intra-individual differences in CRT between Month 3 and 12 were calculated. All statistical analyses were performed with SPSS version 17.0 for Windows (SPSS, Chicago, IL, USA).
Results

Patient characteristics
Overall, 140 eyes from 140 patients were analysed; 70 eyes received ranibizumab PRN and 70 received ranibizumab TE. Patient demographics such as age at diagnosis (78 AE 7 and 79 AE 8 years in the PRN and TE groups, respectively) were well-balanced across the groups for baseline characteristics.
Visual acuity
At baseline, the mean BCVA was the same in both groups (0.39 AE 0.24 and 0.39 AE 0.23, for TE and PRN, respectively; Snellen equivalent 20/51). During the first 3 months, both groups showed analogous improvements in mean BCVA from baseline (TE, +0.14 AE 0.15; PRN, +0.13 AE 0.13; p = 0.676; Fig. 2 ). By Month 6, a significantly greater BCVA gain (compared to baseline) was observed in the TE group compared to the PRN group (+0.16 AE 0.17 and +0.10 AE 0.18, respectively; p = 0.048). At Month 12, mean BCVA was significantly greater in the ranibizumab TE than in the PRN group (0.57 AE 0.26 and 0.46 AE 0.27, respectively; Snellen equivalent 20/35 and 20/43; p = 0.015), this reflected a greater mean BCVA gain from baseline (+0.18 AE 0.17 versus +0.07 AE 0.22, p = 0.001; Fig. 2) . Additionally, mean intra-individual variance in BCVA was significantly lower for patients in the TE group between Months 3 and 12 (0.14 AE 0.12) compared with the PRN group (0.24 AE 0.18; p < 0.001). The difference between the groups was significant during the first period of treatment (until Month 6, except baseline and loading phase) as well as later during the study period (Month 6-12; 0.13 AE 0.10 versus 0.21 AE 0.12, and 0.07 AE 0.08 versus 0.18 AE 0.16, p < 0.001 and p = 0.001, respectively). No change in VA, defined as the same BCVA line assessment at Month 3 and 12 VA examinations, was seen in 42/70 and 22/70 eyes in the TE and PRN groups, respectively.
OCT analysis
Baseline mean CRT was similar between the treatment groups (TE, 428 AE 140 lm; PRN, 415 AE 137 lm). At the first OCT follow-up (Month 1 for TE group, Month 3 for PRN group), a similar percentage of patients in each group showed no intra-or subretinal fluid Study design -PRN and TE treatment regimens. PRN regimen: treatment was initiated with three monthly injections. Retreatment was applied only when any intra-or subretinal fluid or haemorrhages were detected, as assessed by SD-OCT. TE regimen: one injection was administered and BCVA, OCT and biomicroscopic fundus examinations were performed at each visit. The initial treatment interval was 4 weeks, sequentially extended by 2 weeks to a maximum of 12 weeks if no new signs of intra-/subretinal fluid were observed (assessed by OCT), or if no new haemorrhage was observed and intra-/subretinal fluid was stable compared to the two previous visits (provided levels were the lowest since treatment was initiated). Intervals were extended until signs of exudation or new haemorrhage recurred; if a patient twice failed to reach a certain extension, they were reverted to their maximum recurrence-free interval (2 weeks shorter than the failed interval period, minimum interval of 4 weeks). In cases of persisting but stable intra-/subretinal fluid for three consecutive visits, the treatment interval was extended on the condition that the OCT findings remained completely stable without any other signs of disease activity (e.g. haemorrhage). In the case of OCT-observed instability or new CNV activity (haemorrhage), treatment intervals were shortened by 4 weeks to a minimal interval of 4 weeks. BCVA = best corrected visual acuity, CNV = choroidal neovascularization, PRN = pro re nata, SD-OCT = spectral domain optical coherence tomography, TE = treat and extend. Mean (SE) change in BCVA from baseline to study end according to treatment regimen. Treatment-na€ ıve nAMD patients received ranibizumab 0.5 mg according to a TE regimen (n = 70) or a PRN (n = 70) regimen. BCVA (decimal) was measured at each visit and change from baseline in mean values presented for Month 1, 2, 3, 6, 9 and 12. BCVA = best-corrected visual acuity, nAMD = neovascular age-related macular degeneration, PRN = pro re nata, SE = standard error, TE = treat and extend.
(67.1% versus 68.6%). Improvements from baseline in mean CRT were observed in both treatment groups at Month 3 (TE À114 AE 123 versus À104 AE 128 lm; p = 0.638; Fig. 3 ). However, in the PRN group, increases in CRT were observed from Month 6 to 12 (smaller decrease in CRT compared to baseline in the PRN group; Fig. 3 
Treatment frequency
The TE group received significantly more injections during the 12 months of follow-up compared with those in the PRN group (8.6 AE 1.9 versus 6.0 AE 1.9, p < 0.001), while the total number of visits attended was higher in the PRN group than in the TE group (11.9 AE 1.1 versus 8.6 AE 1.9, p < 0.001). At 12 months, the mean maximum period of extension without recurrence was 8.9 AE 3.0 weeks in the TE group. Moreover, 18.6% of treated patients failed to achieve an extension interval >4 weeks, while 37.1% showed stability even with the maximum interval of 12 weeks (Fig. 4) .
The mean number of recurrences requiring either shortening of the interval in the TE schema or retreatment in the PRN schema (Fig. 1 ) was 1.1 AE 0.9 in the TE group from Month 1 to 12, and 3.0 AE 1.9 in the PRN group from Month 3 to 12.
Safety
In the TE treatment regimen, no visionthreatening recurrences or vision-threatening haemorrhages were recorded. In the PRN regimen group, at least one vision-threatening recurrence (vision loss of ≥0.3 during recurrence) or vision-threatening haemorrhage occurred during the 12-month followup period in 32.9% of patients (33/70). Across both groups, no endophthalmitis, further ocular serious adverse events or systemic safety concerns were reported.
Discussion
Although intravitreal anti-VEGF therapy has provided an effective treatment for nAMD Rosenfeld et al. 2006) , the dosing regimen that provides optimal efficacy and safety, whilst minimizing the treatment burden to the patient is still uncertain. Physicians must also consider patient compliance and the healthcare burden associated with a long-term regimen of repeated intravitreal injection and assessment (Spaide 2007) .
Two recent prospective studies (Mantel et al. 2013 (Mantel et al. , 2014 demonstrated that AMD recurrences occur at different lengths of treatment intervals in different patients, therefore supporting the rationale for a TE approach to individualized treatment. Previous small retrospective studies have demonstrated the effectiveness and favourable safety profile of ranibizumab when used in TE regimens (Engelbert et al. 2010; Gupta et al. 2010; Toalster et al. 2013) . Recently, Toalster and colleagues (2013) demonstrated similar improvements in VA (mean improvement of 1.3 lines from baseline; p = 0.008) following 12-month TE dosing of ranibizumab in a multicentre, prospective analysis.
In a retrospective study, the mean improvement in VA after 12 months was significantly greater in the TE group (38 eyes) compared with the PRN group (52 eyes; +10.8 AE 8.8 versus +2.3 AE 17.4 letters, respectively; p = 0.036) (Oubraham et al. 2011) . Our study showed similar findings, with significantly greater improvements from baseline in mean BCVA observed at Month 12 in the TE group than in the PRN group.
As with the long-term clinical trial HORIZON (Singer et al. 2012) , and other prospective and retrospective studies (Gerding et al. 2011; Heimes et al. 2011; Muether et al. 2011) , we observed an initial increase in BCVA during the loading phase of the PRN regimen, which declined gradually over time. Conversely, initial improvements in BCVA seen in the TE group were maintained over the course of the study. Such reductions in BCVA with PRN regimens are not universal, for example initial 12-week BCVA gains were maintained at 2 years during CATT (Martin et al. 2012) , while declines such as those seen in HARBOR (Month 12, +8.2 letters; Month 24 + 7.9 letters) were small (Ho et al. 2014) . These results are from tightly controlled clinical trials and the larger declines in BCVA observed in this study and other retrospective analyses of a PRN regimen (Oubraham et al. 2011; Muether et al. 2013 ) may be indicative of the fact that they are based on the observation of everyday clinical practice, thus capturing all of the variability in patient compliance that this encompasses. The visual outcome results were mirrored by those we observed for the CRT measurements. In the PRN group, initial decreases in CRT at 3 months began to reduce in magnitude, while in the TE group these decreases were sustained at 12 months.
This study is the first to report intraindividual data and demonstrates a significantly smaller fluctuation in the range between the minimum and maximum BCVA and CRT for individual patients in the TE group compared with the PRN group. This is important, as the potential for under-treatment exists with a PRN regimen, as supported by the larger fluctuations seen during this study. Such an approach is potentially detrimental to long-term visual outcomes.
Importantly, the safety profile of ranibizumab in this study was generally similar during both PRN and TE treatment periods, and was comparable to the well-established safety profile reported in previous studies (Engelbert et al. 2010; Gupta et al. 2010; Oubraham et al. 2011; Toalster et al. 2013) ; an increased incidence of vision threatening recurrence or haemorrhage in the PRN versus TE group was the exception.
Our data demonstrated that a TE regimen significantly reduced the number of patient clinic visits in comparison with the monthly visits and diagnostic evaluations necessary for PRN treatment. Moreover, the mean recurrence-free interval during the TE follow-up period was almost 9 weeks; for the majority of patients ranibizumab is effective for longer than 4 weeks, potentially negating the need for monthly injections. The TE regimen may be an attractive alternative for physicians as it may reduce the clinic burden of nAMD treatment.
Patients may consider a clinic visit more worthwhile as part of the TE regimen, since it would always involve both an injection and examination, thus potentially improving compliance. This hypothesis is supported by the findings of Droege and colleagues, who found that patients receiving ranibizumab PRN cited anxiety of a negative examination result as being more pronounced than fear of intraocular injections, which the investigators suggested was an argument for continuous injections rather than a PRN regimen (Droege et al. 2013) .
Although this study is limited by its retrospective nature, the results reported here represent routine clinical practice and provide the first evidence from a large comparative cohort study that ranibizumab administered using a TE regimen can be both effective and well-tolerated in patients with nAMD. Quantifying the burden placed upon healthcare systems by different treatment regimens is needed and requires prospective head-to-head comparison, though previous retrospective analyses support the hypothesis that individualized TE regimens could be associated with lower direct medical costs than those requiring monthly injections (ANCHOR/MARINA) (Gupta et al. 2010) .
In summary, patients receiving ranibizumab in the TE group demonstrated significantly better VA stabilization and significantly fewer patient visits compared to those in the PRN group. Overall, an individualized TE regimen has the potential to reduce clinic burden and improve patient compliance, whilst still maintaining effective and well-tolerated treatment for nAMD. pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 30: 1368-1375. 
